A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
This study is recruiting at 27 US sites in 18 states, according to its ClinicalTrials.gov record last updated .
Summary
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer Harboring BRAF Alterations
- HGG
- LGG
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Fore Biotherapeutics
- Last updated on ClinicalTrials.gov
- July 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Precision NextGen Oncology & Research Center · Beverly Hills, CA
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
- University of California Los Angeles Rheumatology · Westwood, Los Angeles, CA
Connecticut · 1
- Norwalk Hospital · Norwalk, CT
Florida · 1
- University of Miami Hospital and Clinics · Miami, FL
Maryland · 2
- The John Hopkins Hospital · Baltimore, MD
- Maryland Oncology Hematology- Columbia · Rockville, MD
Massachusetts · 2
- Massachusetts General Hospital · Boston, MA
- Tufts Medical Center · Boston, MA
Minnesota · 1
- St. Luke's Hospital · Duluth, MN
Missouri · 1
- Mosaic Life Care at Saint Joseph - Medical Center · Saint Joseph, MO
Nebraska · 1
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy · Omaha, NE
New Jersey · 1
- Overlook Medical Center · Summit, NJ
New York · 2
- Columbia University Irving Medical Center · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
North Carolina · 1
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center · Winston-Salem, NC
Ohio · 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute · Columbus, OH
- Taylor Cancer Research Center · Maumee, OH
Pennsylvania · 1
- Thomas Jefferson University · Philadelphia, PA
Rhode Island · 1
- Lifespan Cancer Institute - Rhode Island Hospital · Providence, RI
Tennessee · 2
- SCRI - TriStar Medical Group Children's Specialists · Nashville, TN
- SCRI Oncology Partners · Nashville, TN
Texas · 3
- Baylor Scott & White Research Institute · Dallas, TX
- University of Texas MD Anderson Cancer Center · Houston, TX
- Baylor Scott & White Medical Center · Temple, TX
Washington · 1
- University of Washington School of Medicine · Seattle, WA
West Virginia · 1
- West Virginia University Health Sciences Campus · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.